Persistent Introduces AI-powered Solution powered by NVIDIA to Enhance Drug Discovery

The solution, named Generative Molecules and Virtual Screening (enMolVS), is built on NVIDIA’s BioNeMo platform and NeMo Agent Toolkit.

Persistent Systems, a global digital engineering and enterprise modernization leader, has announced the launch of an AI-powered generative molecules and virtual screening solution, developed in collaboration with NVIDIA.

The new AI-powered solution seeks to support drug discovery and research by moving from AI experimentation to real-world production deployments in mission-critical environments in the healthcare and life sciences sectors.

The solution, named Generative Molecules and Virtual Screening (enMolVS), is built on NVIDIA’s BioNeMo platform and NeMo Agent Toolkit.

The collaboration will leverage NVIDIA AI Enterprise to support specialised research and development use cases, including preclinical studies.

By applying generative AI and advanced analytics, the solution is intended to help life sciences organisations improve efficiency in the computational drug discovery workflow.

These AI workflows are designed to enable continuous decision-making across virtual screening, candidate prioritization, and downstream experimental planning, helping research teams to translate digital simulations into informed laboratory-based experiments.

This simulation-led approach is expected to support Life Sciences organizations in reducing timelines for early-stage discovery and improving efficiency of the research process across development pipelines.

Further, to support the deployment of production-grade AI applications, Persistent will leverage NVIDIA accelerated computing infrastructure, including the NVIDIA AI Enterprise and NVIDIA NIM microservices.

These capabilities are expected to expedite scalable development and integration of AI models within enterprise environments, supporting real-time scientific analysis.

Commenting on the development, Ganesh Nathella, Executive Vice President and General Manager, Healthcare and Life Sciences Business at Persistent, stated that the combined solution is designed to help biopharma organisations transition from traditional experimentation timelines to AI-supported discovery workflows, while maintaining scientific and regulatory standards.

Commenting on the new initiative, Ganesh Nathella, Executive Vice President and General Manager - HLS Business, Persistent, said, “By combining our GenMolVS solution with NVIDIA's full-stack AI platform, we enable BioPharma clients to use generative molecules and virtual screening in production so they can move from months-long experiments to AI-driven discovery in days, using simulation-led intelligence to guide real-world experimentation without compromising on scientific rigour or compliance.”

In addition, Persistent also plans to expand its AI and large language model (LLM) engineering capabilities by leveraging NVIDIA’s infrastructure, training resources, and certification programmes to develop data-driven platforms for enterprise use.

Highlighting the significance of AI-driven computational research, John Fanelli, Vice President of Enterprise Software at NVIDIA, said, “By leveraging the full-stack NVIDIA AI platform, Persistent is empowering biopharma companies with production-grade agentic systems for molecular simulation and virtual screening.”

Stay tuned for more such updates on Digital Health News